Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

被引：1

作者：

Felipe K. Hurtado

Filippo de Braud

Javier De Castro Carpeño

Maria Jose de Miguel Luken

Ding Wang

Jeffrey Scott

Yvonne Y. Lau

Tracey McCulloch

Morten Mau-Sorensen

机构：

[1] Novartis Pharmaceuticals Corporation,Medical Oncology Department

[2] Fondazione IRCCS-Istituto Nazionale Dei Tumori,Department of Oncology

[3] Hospital Universitario La Paz,undefined

[4] IdiPAZ,undefined

[5] CIOCC-Grupo Hospitalario de Madrid,undefined

[6] Hosp. de Sanchinarro,undefined

[7] Henry Ford Cancer Institute,undefined

[8] Rigshospitalet,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2021年 / 87卷

关键词：

ALK inhibitor; Ceritinib; Drug–drug interaction; Pharmacokinetics; CYP3A; CYP2C9; Midazolam; Warfarin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：475 / 486

页数：11

共 247 条